EMBARK Study: ADT vs Enzalutamide +/-... - Advanced Prostate...

Advanced Prostate Cancer

22,262 members27,955 posts

EMBARK Study: ADT vs Enzalutamide +/- ADT

MateoBeach profile image
5 Replies

Results of the EMBARK study was published this week (10/19/23) in NEJM. It compared high risk BCR PCa treated in 3 groups: Lupron ADT alone. Enzalutamide plus ADT. And Enzalutamide monotherapy. 5 year follow up for metastasis free survival. Results below. Interesting that Enza monotherapy (No ADT) was superior to ADT and nearly as good as the combined treatment.

Details are worth looking at in the full text. Castrate resistance was much lower with combination over ADT as was PSA progression and distant metastasis rates. Enza monotherapy has significant fatigue for many, and significant side effect of gynecomastia as expected with this. (Can be managed by breast radiation or tamoxifen). I don't see where they reported castrate resistance in the monotherapy arm??

This pretty much is the end of ADT monotherapy for the SOC in high risk BCR (or beyond). Those who cannot tolerate enza should pursue darolutamide as the preferred ARSI in my opinion. Paul/MB

nejm.org/doi/pdf/10.1056/NE...

BACKGROUND

Patients with prostate cancer who have high-risk biochemical recurrence have an increased risk of progression. The efficacy and safety of enzalutamide plus an- drogen-deprivation therapy and enzalutamide monotherapy, as compared with androgen-deprivation therapy alone, are unknown.

METHODS

In this phase 3 trial, we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less. Patients were randomly assigned, in a 1:1:1 ratio, to receive enzalutamide (160 mg) daily plus leuprolide every 12 weeks (combination group), placebo plus leuprolide (leuprolide-alone group), or enzalutamide monotherapy (monotherapy group). The primary end point was metastasis-free survival, as assessed by blinded independent central review, in the combination group as compared with the leu- prolide-alone group. A key secondary end point was metastasis-free survival in the monotherapy group as compared with the leuprolide-alone group. Other secondary end points were patient-reported outcomes and safety.

RESULTS

A total of 1068 patients underwent randomization: 355 were assigned to the com- bination group, 358 to the leuprolide-alone group, and 355 to the monotherapy group. The patients were followed for a median of 60.7 months. At 5 years, metas- tasis-free survival was 87.3% (95% confidence interval [CI], 83.0 to 90.6) in the combination group, 71.4% (95% CI, 65.7 to 76.3) in the leuprolide-alone group, and 80.0% (95% CI, 75.0 to 84.1) in the monotherapy group. With respect to metas- tasis-free survival, enzalutamide plus leuprolide was superior to leuprolide alone (hazard ratio for metastasis or death, 0.42; 95% CI, 0.30 to 0.61; P<0.001); enzaluta- mide monotherapy was also superior to leuprolide alone (hazard ratio for metastasis or death, 0.63; 95% CI, 0.46 to 0.87; P=0.005). No new safety signals were observed, with no substantial between-group differences in quality-of-life measures.

CONCLUSIONS

In patients with prostate cancer with high-risk biochemical recurrence, enzalu- tamide plus leuprolide was superior to leuprolide alone with respect to metastasis- free survival; enzalutamide monotherapy was also superior to leuprolide alone. The safety profile of enzalutamide was consistent with that shown in previous clinical studies, with no apparent detrimental effect on quality of life. (Funded by Pfizer and Astellas Pharma; EMBARK ClinicalTrials.gov number, NCT02319837.

Written by
MateoBeach profile image
MateoBeach
To view profiles and participate in discussions please or .
Read more about...
5 Replies
GP24 profile image
GP24

Enzalutamide monotherapy does not lower testosterone and therefore has fewer side effects compared to ADT plus Enzalutamide. On the other hand it is not quite as effective as ADT plus Enzalutamide. When should you select Enzalutamide monotherapy then?

TN1932 profile image
TN1932 in reply toGP24

How about in the case that one had been on ADT for long time and testosterone never can recover after?

GP24 profile image
GP24 in reply toTN1932

It usually recovers a little bit, enough to feed the cancer.

treedown profile image
treedown

Just as a note, I did not tolerate Xtandi and did pursue Daralutamide and was denied by insurance. Back on AA.

MateoBeach profile image
MateoBeach

Yes that is a problem I recognize. Perhaps getting MO to apply for an exception due risks of falls or seizures from Enza

Not what you're looking for?

You may also like...

Xtandi monotherapy is very effective

(Zoom your browser to read the image) At the AUA2023 the results of the EMBARK trial were...
GP24 profile image

EMBARK trial results reported

Pfizer reported results of the EMBARK trial testing Xtandi+Lupron or Xtandi alone against...
GP24 profile image

Statin use in advanced PCA with ADT or abiraterone/enzalutamide

New meta-analysis below [1]. Does statin use affect mortality when used with classic ADT or...
pjoshea13 profile image

EMBARK trial results already available?

EMBARK is a randomized Phase 3 study of enzalutamide plus leuprolide, enzalutamide monotherapy, and...
GP24 profile image

Management of the Metastases in Oligometastatic Prostate Cancer

Until recently, there has been very little data supporting non-cranial stereotactic body...
George71 profile image